Maternal probiotic supplementation for improved neurodevelopmental outcomes in infants of diabetic mothers (IDMs)

Status: Recruiting

Eligibility Criteria

Sex: Female
Age Group: 18 years and over
This study is also accepting healthy volunteers

Inclusion Criteria:

- pregnant women in their second or third trimester with a diagnosis of gestational diabetes - screening for gestational diabetes involves a 2-step (screening test followed by a diagnostic test) with screening done between 24 and 28 weeks of gestation in a non-fasting state. If the screening threshold is met or exceeded, patients receive a oral glucose tolerance test (OGTT) - BMI 18.5-45 kg/m2 at first prenatal visit - age 21-45 at time of delivery - pregnant women who report during enrollment procedures that they have social support for and intention to exclusively breastfeed for at least 3 months (breastfeeding intentions are known to be correlated with actual behavior) - single pregnancy

Exclusion Criteria:

- alcohol consumption >1 drink per week during pregnancy/lactation - tobacco consumption during pregnancy or lactation - inability to speak and understand English - known congenital metabolic, endocrine disease (other than GDM), or congenital illness affecting infant feeding - history of type I Diabetes - mothers currently taking over the counter probiotic preparation

Conditions & Interventions

Interventions:
Dietary Supplement: Probiotic Supplement
Conditions:
Women's Health
Keywords:
women's health, pregnancy, pregnant women, gestational diabetes

More Information

Description: The purpose of this study is to see whether providing pregnant women with probiotics during their pregnancy is associated with infant gut microbiome variation and improved neurodevelopmental outcomes. We expect that you and your child will be in this research study for approximately 8 months from the time you sign the consent from to the completion of your 6-month visit with your infant.
Study Contact: Maria Bunch - mbunch@umn.edu
Principal Investigator: Marie Hickey
Phase: NA
IRB Number: STUDY00016313